SCHEMBL6976982

SCHEMBL6976982

COc1ccc(CN(CC(=O)O)S(=O)(=O)c2ccc3c(Cl)cnc(NC(=N)N)c3c2)cc1

nearest known ligand 0.58

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PLAU P00749 5/20 0.58
MEP1B Q16820 2/20 0.47
PLG P00747 1/20 0.46
KEAP1 Q14145 1/20 0.45
DAGLA Q9Y4D2 2/20 0.44
ALDH1A1 P00352 2/20 0.44
LMNA P02545 1/20 0.44
TSHR P16473 1/20 0.44
TAS2R14 Q9NYV8 5/20 0.43
BMP1 P13497 1/20 0.43
MMP3 P08254 1/20 0.42
ADAM10 O14672 1/20 0.42
MMP2 P08253 1/20 0.42
MMP9 P14780 1/20 0.42
MMP13 P45452 1/20 0.42
ADAM17 P78536 1/20 0.42
MEP1A Q16819 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6433152 0.91 PLAU (0.57) PLAUMEP1BPLGDAGLALMNA
SCHEMBL6437213 0.90 PLAU (0.46) PLAUMEP1BALDH1A1LMNATSHR
Hydrochloric Acid SCHEMBL6438528 0.89 PLAU (0.46) PLAUMEP1BALDH1A1LMNATSHR
Hydrochloric Acid SCHEMBL6434573 0.87 PLAU (0.60) PLAUPLGDAGLAALDH1A1MMP2
Hydrochloric Acid SCHEMBL6435316 0.86 PLAU (0.56) PLAUPLG
Trifluoroacetic Acid SCHEMBL6435143 0.85 PLAU (0.65) PLAUPLGDAGLAALDH1A1MMP2
Hydrochloric Acid SCHEMBL6437626 0.83 PLAU (0.60) PLAUPLGDAGLAALDH1A1MMP9
SCHEMBL7377719 0.82 PLAU (0.58) PLAUPLGKEAP1ALDH1A1LMNA
SCHEMBL6432627 0.82 PLAU (0.56) PLAUPLGALDH1A1LMNATSHR
Trifluoroacetic Acid SCHEMBL6437834 0.81 PLAU (0.50) PLAUPLGKEAP1DAGLAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030199440-A1 Composition for the treatment of damaged tissue PFIZER INC. 2003-10-23 US disclosed
EP-1077945-B1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER (US) 2003-01-08 EP disclosed
EP-1242120-A2 COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE Pfizer Limited (GB) 2002-09-25 EP disclosed
WO-2001049309-A2 COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE PFIZER LIMITED (GB) 2001-07-12 WO disclosed
EP-1077945-A1 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2001-02-28 EP disclosed
US-6093731-A Isoquinolines PFIZER INC. 2000-07-25 US disclosed
WO-2000005214-A2 ISOQUINOLINES AS UROKINASE INHIBITORS PFIZER INC. (US) 2000-02-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030199440-A1 Composition for the treatment of damaged tissue MMP1, SERPINE1, COL14A1 PLAU 119/4885MEP1B 1165/4885PLG 33/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.